These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 32991142)
1. Characterization of Moxidectin against Buchter V; Hofmann D; Häberli C; Keiser J ACS Infect Dis; 2021 May; 7(5):1069-1076. PubMed ID: 32991142 [No Abstract] [Full Text] [Related]
2. Efficacy and safety of moxidectin compared with ivermectin against Strongyloides stercoralis infection in adults in Laos and Cambodia: a randomised, double-blind, non-inferiority, phase 2b/3 trial. Sprecher VP; Hofmann D; Savathdy V; Xayavong P; Norkhankhame C; Huy R; Khieu V; Sayasone S; Hattendorf J; Keiser J Lancet Infect Dis; 2024 Feb; 24(2):196-205. PubMed ID: 37949090 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial. Hofmann D; Sayasone S; Sengngam K; Chongvilay B; Hattendorf J; Keiser J Lancet Infect Dis; 2021 Aug; 21(8):1151-1160. PubMed ID: 33798487 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Moxidectin Versus Ivermectin Against Strongyloides stercoralis Infections: A Randomized, Controlled Noninferiority Trial. Barda B; Sayasone S; Phongluxa K; Xayavong S; Keoduangsy K; Odermatt P; Puchkov M; Huwyler J; Hattendorf J; Keiser J Clin Infect Dis; 2017 Jul; 65(2):276-281. PubMed ID: 28369530 [TBL] [Abstract][Full Text] [Related]
5. Assessment of FDA-approved drugs against Strongyloides ratti in vitro and in vivo to identify potentially active drugs against strongyloidiasis. Keiser J; Häberli C Parasit Vectors; 2021 Dec; 14(1):615. PubMed ID: 34949209 [TBL] [Abstract][Full Text] [Related]
6. Comparative evaluation of Strongyloides ratti and S. stercoralis larval antigen for diagnosis of strongyloidiasis in an endemic area of opisthorchiasis. Eamudomkarn C; Sithithaworn P; Sithithaworn J; Kaewkes S; Sripa B; Itoh M Parasitol Res; 2015 Jul; 114(7):2543-51. PubMed ID: 25877389 [TBL] [Abstract][Full Text] [Related]
7. Strongyloides ratti: in vitro and in vivo activity of tribendimidine. Keiser J; Thiemann K; Endriss Y; Utzinger J PLoS Negl Trop Dis; 2008 Jan; 2(1):e136. PubMed ID: 18235851 [TBL] [Abstract][Full Text] [Related]
8. Cryo-microtome sections of coproculture larvae of Strongyloides stercoralis and Strongyloides ratti as antigen sources for the immunodiagnosis of human strongyloidiasis. Costa-Cruz JM; Bullamah CB; Gonçalves-Pires Mdo R; Campos DM; Vieira MA Rev Inst Med Trop Sao Paulo; 1997; 39(6):313-7. PubMed ID: 9674280 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the Population Pharmacokinetics of Moxidectin in Adults Infected with Strongyloides Stercoralis: Support for a Fixed-Dose Treatment Regimen. Smit C; Hofmann D; Sayasone S; Keiser J; Pfister M Clin Pharmacokinet; 2022 Jan; 61(1):123-132. PubMed ID: 34296417 [TBL] [Abstract][Full Text] [Related]
10. Development and validation of an LC-MS/MS method for the quantification of the anthelmintic drug moxidectin in a volumetric absorptive microsample, blood, and plasma: Application to a pharmacokinetic study of adults infected with Strongyloides stercoralis in Laos. Hofmann D; Sayasone S; Keiser J J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Mar; 1166():122556. PubMed ID: 33535101 [TBL] [Abstract][Full Text] [Related]
11. Evaluating alternative compounds for strongyloidiasis therapy: Novel insights from larval migration inhibition test. Cambra-Pellejà M; Valderas-García E; Balaña-Fouce R; de la Vega J; Del Olmo E; Antwi-Ekwuruke J; Linnemann L; Heepmann L; Breloer M; Martínez-Valladares M PLoS Negl Trop Dis; 2024 Oct; 18(10):e0012532. PubMed ID: 39374184 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of albendazole against Strongyloides ratti and S. stercoralis in vitro, in mice, and in normal and immunosuppressed dogs. Grove DI; Lumsden J; Northern C J Antimicrob Chemother; 1988 Jan; 21(1):75-84. PubMed ID: 3356624 [TBL] [Abstract][Full Text] [Related]
13. Moxidectin: an ally to ivermectin for treating Strongyloides stercoralis? Bisoffi Z; Buonfrate D Lancet Infect Dis; 2021 Aug; 21(8):1060-1061. PubMed ID: 33798488 [No Abstract] [Full Text] [Related]
14. Efficacy of ivermectin against Strongyloides stercoralis infection in jirds (Meriones unguiculatus). Sithithaworn P; Fujimaki Y; Mitsui Y; Prasanthong R; Yutanawiboonchai W; Aoki Y Exp Parasitol; 1998 Jun; 89(2):205-12. PubMed ID: 9635444 [TBL] [Abstract][Full Text] [Related]
15. Assay of nematocidal activity of isoquinoline alkaloids using third-stage larvae of Strongyloides ratti and S. venezuelensis. Satou T; Koga M; Matsuhashi R; Koike K; Tada I; Nikaido T Vet Parasitol; 2002 Mar; 104(2):131-8. PubMed ID: 11809332 [TBL] [Abstract][Full Text] [Related]
16. IgG1, IgG4, and IgE antibody responses in human strongyloidiasis by ELISA using Strongyloides ratti saline extract as heterologous antigen. Rodrigues RM; de Oliveira MC; Sopelete MC; Silva DA; Campos DM; Taketomi EA; Costa-Cruz JM Parasitol Res; 2007 Oct; 101(5):1209-14. PubMed ID: 17610082 [TBL] [Abstract][Full Text] [Related]
17. Histopathological confirmation of disseminated larvae (iL3) of Strongyloides ratti in an immunosuppressed Wistar rat. Mahmuda A; Al-Zihiry KJK; Roslaini AM; Rukman AH; Abdulhaleem N; Bande F; Mohammed AA; Alayande MO; Abdullah WO; Zasmy U Trop Biomed; 2017 Mar; 34(1):212-223. PubMed ID: 33593000 [TBL] [Abstract][Full Text] [Related]
18. The effect of non-immune stresses on the development of Strongyloides ratti. Crook M; Viney ME Parasitology; 2005 Sep; 131(Pt 3):383-92. PubMed ID: 16178360 [TBL] [Abstract][Full Text] [Related]
19. Life cycle stage-resolved proteomic analysis of the excretome/secretome from Strongyloides ratti--identification of stage-specific proteases. Soblik H; Younis AE; Mitreva M; Renard BY; Kirchner M; Geisinger F; Steen H; Brattig NW Mol Cell Proteomics; 2011 Dec; 10(12):M111.010157. PubMed ID: 21964353 [TBL] [Abstract][Full Text] [Related]
20. Vaccination with Strongyloides ratti heat shock protein 60 increases susceptibility to challenge infection by induction of Th1 response. Nouir NB; Eschbach ML; Piédavent M; Osterloh A; Kingsley MT; Erttmann K; Brattig N; Liebau E; Fleischer B; Breloer M Vaccine; 2012 Jan; 30(5):862-71. PubMed ID: 22172506 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]